VIRTUOZZO
3.6.2021 12:32:08 CEST | Business Wire | Press release
Virtuozzo , a global leader in high-efficiency virtualization and hyperconverged software solutions, has welcomed Mick Bradley as its new Vice President of Global Sales. Mick joins Virtuozzo with over 25 years of sales leadership and management experience in the IT/Software industry, including a strong track record of building successful teams in early and growth-stage organizations while driving sales excellence and partner strategies. Mick will steer Virtuozzo’s global sales team executing the overall sales strategy, including expanding and improving its sales capabilities to support the growth of new customers and its core customer base – Virtuozzo’s network of 450+ service provider partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005288/en/
Mick’s appointment comes at a pivotal time for Virtuozzo as the Company accelerates growth in new and existing markets. Virtuozzo’s product portfolio is well suited to provide end-to-end cloud enablement for the fast-growing service provider market – both hosting service providers and the Company’s new vertical focus, managed and cloud service providers. Mick’s expertise and leadership will help drive the Company’s strategic vision and accelerate its growth, building upon over 21 years of innovation in the virtualization software business.
Previously Mick served as Senior Vice President & General Manager for EMEA at Arcserve, where he developed and implemented a strategy to move Arcserve from SMB into mid-markets and SME, resulting in significant revenue growth, channel expansion, and a successful transition to cloud service. Prior to this, he held several senior positions, including VP & General Manager for EMEA at Kaminario Inc., EMEA Managing Director at Violin Memory, Senior Director of EMEA Storage Consulting at Hewlett Packard, Chief Operating Officer at CopperEye, and Senior Vice President of Global Services at COPAN Systems.
“We’re thrilled to welcome Mick at such a critical time in Virtuozzo’s evolution. His extensive leadership and sales expertise will help establish Virtuozzo as the global leader in hybrid cloud enablement for the service provider market. Under Mick’s leadership, our sales team is well positioned to continue accelerating our business with a strong global team, solid solution portfolio, and a customer base of 450 service providers worldwide. With his expertise in growing both global and startup sales organizations in the software industry, Mick will bring our business to the next level. We couldn't be more excited," said Alex Fine, CEO, Virtuozzo.
“I’m joining Virtuozzo during an exciting time for both the Company and our partners and look forward to leveraging my experience to help both achieve massive growth. Virtuozzo’s ability to quickly offer cutting-edge cloud services is a game-changer for service providers seeking to differentiate and disrupt today. I am thrilled to be joining Virtuozzo and look forward to great things to come,” remarked Mick Bradley, VP of Global Sales, Virtuozzo.
About Virtuozzo
Virtuozzo is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel. Learn more https://go.virtuozzo.com/l/148051/2021-06-02/5kjhgs .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005288/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom